Market Place
Sourcing Support
Immunic Publishes Phase 1/1b Data for IMU-856 in The Lancet
13 Nov 2024 //
PR NEWSWIRE
Immunic to Report Q3 2024 Results and Corporate Update
31 Oct 2024 //
PR NEWSWIRE
Immunic To Attend Industry And Investor Conferences In November
29 Oct 2024 //
PR NEWSWIRE
Immunic Announces Positive Interim Analysis Of Phase 3 ENSURE
22 Oct 2024 //
PR NEWSWIRE
Immunic Presents Vidofludimus Data at ECTRIMS 2024 for MS Treatment
18 Sep 2024 //
PR NEWSWIRE
Immunic Enrolls First Patient in Ph 2 Trial of Vidofludimus Calcium
04 Sep 2024 //
PR NEWSWIRE
Immunic To Host MS R&D Day And Attend September Conferences
28 Aug 2024 //
PR NEWSWIRE
Immunic Reports Q2 2024 Results And Provides Corporate Update
08 Aug 2024 //
PR NEWSWIRE
Immunic To Report Q2 2024 Results
01 Aug 2024 //
PR NEWSWIRE
Immunic Appoints Jason Tardio as Chief Operating Officer and President
09 Jul 2024 //
PR NEWSWIRE
Immunic to Participate in Industry and Scientific Conferences in June
28 May 2024 //
PR NEWSWIRE
Immunic Q1 2024 Results, Corporate Update
01 May 2024 //
PR NEWSWIRE
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
04 Apr 2024 //
PR NEWSWIRE
Immunic Receives Notice of Allowance for Composition-of-Matter Patent
20 Mar 2024 //
PR NEWSWIRE
Immunic Presents Data From Phase 2 Trials of Vidofludimus Calcium
29 Feb 2024 //
PR NEWSWIRE
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023
15 Feb 2024 //
PR NEWSWIRE
Immunic, Inc. Announces Private Placement of up to $240 Million
05 Jan 2024 //
PR NEWSWIRE
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
05 Jan 2024 //
PR NEWSWIRE
Immunic to Announce Financial Results for the Third Quarter
07 Nov 2023 //
PR NEWSWIRE
Immunic to Participate in Scientific and Industry Conferences in November
26 Oct 2023 //
PR NEWSWIRE
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium
16 Oct 2023 //
PR NEWSWIRE
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856
15 Oct 2023 //
PR NEWSWIRE
Immunic`s investors appeased by biomarker data from MS trial
10 Oct 2023 //
FIERCE BIOTECH
Immunic to Participate in Scientific Conferences in October
04 Oct 2023 //
PR NEWSWIRE
Immunic Completes Enrollment of Phase 2 CALLIPER Trial of Vidofludimus Calcium
17 Aug 2023 //
PR NEWSWIRE
Immunic, Inc. Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
PR NEWSWIRE
Immunic to Participate in Investor and Scientific Conferences in August
01 Aug 2023 //
PR NEWSWIRE
Immunic, Inc. to Announce Financial Results for the Second Quarter
27 Jul 2023 //
PR NEWSWIRE
Immunic to Participate in Scientific and Investor Conferences in June
30 May 2023 //
PR NEWSWIRE
Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator
17 May 2023 //
PR NEWSWIRE
Immunic, Inc. Reports 1Q 2023 Financial Results and Provides Corporate Update
11 May 2023 //
PR NEWSWIRE
Immunic, Inc. to Announce FYR for the 1Q Ended March 31, 2023, & Provide Update
09 May 2023 //
PR NEWSWIRE
Immunic Strengthens Its BOD with the Appointment of Richard Rudick, M.D.
27 Apr 2023 //
PR NEWSWIRE
Immunic touts positive data in maintenance phase of failed PhII trial, pulls back asset
07 Apr 2023 //
ENDPTS
Immunic Reports Positive Data from PII CALDOSE-1 Trial of Vidofludimus Calcium
05 Apr 2023 //
PR NEWSWIRE
Immunic punts psoriasis and prostate programs to narrow focus
05 Apr 2023 //
FIERCE BIOTECH
Immunic to Participate in Investor and Scientific Conferences in March
02 Mar 2023 //
PR NEWSWIRE
Immunic Reports Year End 2022 Financial Results and Provides Corporate Update
23 Feb 2023 //
PR NEWSWIRE
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
22 Feb 2023 //
PR NEWSWIRE
Immunic to Announce Financial Results for the Year Ended December 31, 2022
16 Feb 2023 //
PR NEWSWIRE
Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways
09 Feb 2023 //
PR NEWSWIRE
Immunic to Participate in Scientific and Investor Conferences in February
25 Jan 2023 //
PR NEWSWIRE
Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
17 Nov 2022 //
PRNEWSWIRE
Immunic to Participate in Investor and Scientific Conferences in Nov
10 Nov 2022 //
PRNEWSWIRE
Immunic, Inc. Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
PRNEWSWIRE
Immunic to Announce Financial Results for the Q3 Ended September 30, 2022,
27 Oct 2022 //
PRNEWSWIRE
Dreaded `high placebo rate` hits Immunic`s psoriasis trial
22 Oct 2022 //
FIERCEBIOTECH
Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935
20 Oct 2022 //
PRNEWSWIRE
Immunic Announces $60.0M Oversubscribed Private Placement Equity Financing
10 Oct 2022 //
PRNEWSWIRE
Immunic to Participate in Scientific and Industry Conferences in October
04 Oct 2022 //
PRNEWSWIRE
Immunic Announces Positive Results from PI Clinical Trial of IMU-856
20 Sep 2022 //
PRNEWSWIRE
Immunic, Inc. to Participate in Investor Conferences in September
01 Sep 2022 //
PRNEWSWIRE
Immunic Gets Notice of Allowance for Composition-of-Matter Patent for IMU-856
16 Aug 2022 //
PRNEWSWIRE
Immunic to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
02 Aug 2022 //
PRNEWSWIRE
Immunic Strengthens Its Board of Directors with the Appointment of Maria Törnsén
06 Jul 2022 //
PRNEWSWIRE
Immunic to Participate in Industry and Scientific Conferences in July
28 Jun 2022 //
PRNEWSWIRE
Immunic regains some momentum with multiple sclerosis update
16 Jun 2022 //
FIERCEBIOTECH
Immunic to Participate in Scientific, Industry and Investor Conferences in June
08 Jun 2022 //
PRNEWSWIRE
Immunic shares cut in half as biotech dumps ulcerative colitis after PhII fail
04 Jun 2022 //
ENDPTS
